Recently, Pfizer was denied institution of two follow-on inter partes review (IPR) petitions, IPR Nos. 2018-00330 and 2018-00331 (“the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
BiosimilarsIP.com News section provides updates on current news and events related to biologics and biosimilars.
-
-
Earlier this month, Amgen initiated suit against Apotex in the Middle District of Florida, alleging infringement of U.S. Patent No....
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
In a 104-page ruling, U.S. District Judge Mark L. Wolf granted summary judgment in favor of Celltrion and Hospira, finding that a doctrine...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On August 10, 2018, AbbVie, Inc. and AbbVie Biotechnology Ltd. (collectively “AbbVie”) sued Sandoz Inc., Sandoz GMBH, and Sandoz...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The PTAB recently instituted a second IPR of US Patent 9,296,821 (“the ’821 patent”), which covers certain uses of Rituxan®...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
U.S. Patent No. 8,329,172 (“the ’172 patent”), a Biogen-owned patent covering a treatment regime for low-grade B-cell non-Hodgkin’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On July 2, 2018, Genentech filed suit against Eli Lilly and Company (“Lilly”) in the Southern District of California alleging Lilly’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]